Orgenesis (NASDAQ:ORGS), Inc. is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system. Orgenesis also provides custom reagent kits, clinical-grade raw materials, and proprietary lentiviral vectors to support the development and manufacture of personalized cell therapies. In addition, the company’s CGTP (Cell and Gene Therapy Platform) solutions help biopharma partners accelerate timelines by enabling on-site production at academic and hospital settings.
Founded in 2003 and headquartered in Germantown, Maryland, Orgenesis operates through subsidiaries in Europe and Asia, including development and manufacturing facilities in Belgium and Singapore. The company has established collaborations with leading hospitals and research institutions to pilot its point-of-care model and validate therapy workflows across multiple geographies. These partnerships aim to reduce costs, improve accessibility and maintain quality standards for advanced cell and gene therapies.
Orgenesis is led by founder and Chief Executive Officer Dr. Nadim Yared, whose background in genetics and medical technology has driven the company’s focus on decentralized manufacturing. Under Yared’s direction, Orgenesis continues to expand its global footprint and invest in novel platforms designed to bring transformative therapies closer to patients.
